Galectin-3 as a marker of interstitial atrial remodelling involved in atrial fibrillation

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Hernández Romero, Diana ^a   Vílchez, Juan Antonio ^a   Lahoz, Álvaro ^a   Romero Aniorte, Ana I ^a   Jover, Eva ^a   García Alberola, Arcadio ^a   Jara Rubio, Rubén ^b   Martínez, Carlos M ^c   Valdés, Mariano ^a   Marín, Francisco ^a  

^a IMIB Arrixaca from Murcia ^*  (Spain)

^b Intensive Care Unit   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GALECTIN 3; GALECTIN-3, HUMAN;

AGED; ATRIAL FIBRILLATION; BLOOD; CARDIAC MUSCLE; FEMALE; FIBROSIS; HEART ATRIUM REMODELING; HUMAN; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL;

AGED; ATRIAL FIBRILLATION; ATRIAL REMODELING; BIOMARKERS; FEMALE; FIBROSIS; GALECTIN 3; HUMANS; LINEAR MODELS; MALE; MYOCARDIUM; ROC CURVE;

EID: 85009471195     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep40378     Document Type: Article

References (16)

1. Nattel, S., Burstein, B. & Dobrev, D. Atrial remodelling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 1, 62-73 (2008).
2. Go, A. S. et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 285, 2370-5 (2001).
3. Arribas-Leal, J. M. et al. Epidemiology and new predictors of atrial fibrillation after coronary surgery. Rev Esp Cardiol. 60, 841-7 (2007).
4. Benjamin, E. J. et al. Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study. JAMA. 271, 840-4 (1994).
5. Orenes-Pinero, E. et al. Pre and post-operative treatments for prevention of atrial fibrillation after cardiac surgery. Mini Rev Med Chem. 12, 1419-31 (2012).
6. Sanchez-Quinones, J., Marin, F., Roldan, V. & Lip, G. Y. The impact of statin use on atrial fibrillation. QJM. 10, 1845-61 (2008).
7. de Boer, R. A., Yu, L. & van Veldhuisen, D. J. Galectin-3 in cardiac remodelling and heart failure. Curr Heart Fail Rep. 7, 1-8 (2010).
8. Sharma, U. C. et al. Galectin-3 marks activated macrophages in failureprone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 110, 3121-3128 (2004).
9. Liu, Y. H. et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodelling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol. 296, H404-H412 (2009).
10. Allessie, M., Ausma, J. & Schotten, U. Electrical, contractile and structural remodelling during atrial fibrillation. Cardiov Res. 54, 230-46 (2002).
11. Hernandez-Romero, D. et al. High-sensitivity troponin T as a biomarker for the development of atrial fibrillation after cardiac surgery. Eur J Cardiothorac Surg. 45, 733-8 (2014).
12. Hernandez-Romero, D. et al. VonWillebrand factor is associated with atrial fibrillation development in ischaemic patients after cardiac surgery. Europace. Nov 12, pii: euv354 [Epub ahead of print] (2015).
13. Yalcin, M. U. et al. J Cardiovasc Electrophysiol. 26, 635-40 (2015).
14. Fox, K. F. et al. Report on the European Association of Echocardiography accreditations in echocardiography: December 2003-September 2006. Eur J Echocardiogr. 8, 74-9 (2007).
15. Lang, R. M. et al. Recommendations for chamber quantification. Eur J Echocardiogr. 7, 79-108 (2006).
16. Gehan, E. A. & George, S. L. Estimation of human body surface area from height and weight. Cancer Chemother Rep. 54, 225-35 (1970).